Orbimed Advisors LLC Otonomy, Inc. Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $3.97 Million - $7.15 Million	-3,250,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.16 - $4.36 $10.3 Million - $14.2 Million	3,250,000 New	3,250,000 $13.2 Million
Q2 2020 Aug 14, 2020	SELL	$1.87 - $3.84 $134,628 - $276,456	-71,994 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.58 - $4.06 $440,355 - $1.13 Million	-278,706 Reduced 79.47%	71,994 $142,000
Q4 2019 Feb 14, 2020	BUY	$2.13 - $3.83 $746,991 - $1.34 Million	350,700 New	350,700 $1.34 Million
Q4 2017 Feb 14, 2018	SELL	$2.8 - $5.55 $1.8 Million - $3.57 Million	-644,074 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$3.2 - $20.8 $2.06 Million - $13.4 Million	644,074	644,074 $2.09 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.